Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer
NCT01764022Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Oct 2012
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of BCD-022 in HER2-positive metastatic breast cancer (2 arms), sponsored by BIOCAD. Primary endpoints: Overall Response Rate at Day 127 and Area Under the Curve at Day 22. Started Oct 2012; status: completed.
02
Drugs
BCD-022
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01764022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01764022.